About Gilead Sciences

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company specializes in several therapeutic areas, including HIV/AIDS, liver diseases, hematology/oncology, cardiovascular, and inflammation/respiratory diseases. Gilead is committed to advancing healthcare by addressing unmet medical needs and improving life outcomes for patients around the globe. Their operations span research and development, manufacturing, and the commercialization of their products in various countries. Through collaborations and partnerships, Gilead aims to accelerate the development of novel therapies and expand its product portfolio to make a significant impact in the realm of healthcare.

Snapshot

Public USOwnership

1987Year founded

14488Employees

Foster City, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

United States

Products and/or services of Gilead Sciences

HIV/AIDS antiretroviral medications, providing life-saving treatments to millions globally.
Hepatitis C treatments, significantly improving cure rates for patients.
COVID-19 treatment Remdesivir, used globally to treat severe cases.
CAR T-cell therapies for certain types of blood cancer, offering innovative treatment options.
Hepatitis B medications, managing chronic infections and reducing health complications.
HIV PrEP (Pre-exposure Prophylaxis), reducing the risk of HIV infection in high-risk populations.

Gilead Sciences executive team

Mr. Daniel P. O'DayChairman & CEO
Mr. Andrew D. DickinsonChief Financial Officer
Ms. Johanna MercierChief Commercial & Corporate Affairs Officer
Ms. Erin BurkhartSVP, Controller & Principal Accounting Officer
Ms. Jacquie Ross C.F.A.Senior Vice President of Treasury and Investor Relations
Ms. Keeley WettanExecutive VP and General Counsel of Legal & Compliance
Ms. Jyoti K. MehraExecutive Vice President of Human Resources
Dr. Linda Slanec Higgins Ph.D.Senior Vice President of Research, Innovation & Portfolio
Dr. Flavius Martin M.D.Executive Vice President of Research
Ms. Janet DorlingSenior Vice President of Intercontinental Region & Global Patient Solutions